ArticleClinical kidney journal2026
Current practices in antibiotic prophylaxis for patients on complement inhibitors: a multicenter survey across ERN ERKnet centers.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Complement inhibitors such as eculizumab and ravulizumab are increasingly used to treat rare complement-mediated diseases. While effective, these therapies impair host defenses against encapsulated bacteria, leading to a heightened risk of invasive infections. Although vaccination is standard, the role and implementation of antibiotic prophylaxis remain inconsistent across clinical settings. Methods: A survey was conducted among European Reference Network for Rare Kidney Diseases (ERN ERKNet) centers to assess current practices regarding antibiotic prophylaxis in patients receiving complement-inhibition therapy. The survey addressed four clinical scenarios-pediatric vs. adult, transplant recipient vs. non-transplant-and explored three domains: indications for prophylaxis, choice of antibiotic, and duration. Results: Twenty-seven centers from 16 European countries participated. Systematic prophylaxis was widely endorsed, particularly for pediatric patients and transplant recipients. Penicillin-class antibiotics were preferred as first-line agents across all groups. In pediatric settings, phenoxymethylpenicillin and amoxicillin were most commonly used, whereas adult regimens included penicillin or fluoroquinolones for those with allergies. Most respondents recommended continuing prophylaxis throughout the duration of complement-inhibition therapy, regardless of vaccination status. The survey revealed areas of heterogeneity in practice, especially regarding allergy management and the duration of post-vaccination coverage. Conclusions: This ERKNet survey identifies prevailing practices and variation in antibiotic prophylaxis for patients receiving complement-inhibition therapy. Based on these findings, we propose consensus guidance to support harmonized, risk-adapted prophylaxis strategies across pediatric and adult populations. These guidance statements aim to address an important unmet need in infection prevention among complement-inhibited patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.